<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477605</url>
  </required_header>
  <id_info>
    <org_study_id>VRH172-P001</org_study_id>
    <nct_id>NCT02477605</nct_id>
  </id_info>
  <brief_title>Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes</brief_title>
  <official_title>Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the treatment day change between immediate
      postoperative and immediate preoperative intraocular pressure (IOP) between 27-gauge and
      23-gauge vitrectomy instruments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Required follow-up for this study is 3 months post treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2015</start_date>
  <completion_date type="Actual">August 31, 2016</completion_date>
  <primary_completion_date type="Actual">June 1, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Intraocular Pressure (IOP) on Operative Day</measure>
    <time_frame>Day 0 preoperative, Day 0 postoperative</time_frame>
    <description>IOP (fluid pressure inside the eye) was assessed using the study specified tono-pen and measured in millimeters of mercury (mmHg). Change was defined as the difference between immediate postoperative IOP and immediate preoperative IOP. A greater change in IOP may indicate a less stable posterior chamber and/or a more invasive surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Conjunctival Edema Score at Week 1</measure>
    <time_frame>Week 1 post operative</time_frame>
    <description>Conjunctival edema (swelling) was assessed during examination by the investigator and graded on a scale of 0-3, where 0=Absent and 3=Severe. Each sclerotomy wound was graded as infusion, vitrectomy probe, and illuminator and the average of the three was the overall Conjunctival Edema Score at the visit. Only one eye (study eye) contributed to the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Post-operative Pain Rating at Day 1</measure>
    <time_frame>Day 1 post operative</time_frame>
    <description>The subject was asked to rate post-operative pain in the study eye using a score of 0-10, where 0=no pain and 10=the worst pain imaginable.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Vitreoretinal Disease</condition>
  <arm_group>
    <arm_group_label>27-gauge pak</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONSTELLATION® 27-gauge combined surgical pak used during vitrectomy surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>23-gauge pak</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CONSTELLATION® 23-gauge combined surgical pak used during vitrectomy surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CONSTELLATION® 27-gauge Combined Surgical Pak</intervention_name>
    <description>Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 27-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 27-gauge EDGEPLUS® Valved Entry System comprised of 3 trocar/cannulas and related accessories.</description>
    <arm_group_label>27-gauge pak</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CONSTELLATION® 23-gauge Combined Surgical Pak</intervention_name>
    <description>Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 23-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 23-gauge EDGEPLUS® trocar/cannula set comprising of 3 trocars/cannulas and related accessories.</description>
    <arm_group_label>23-gauge pak</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vitrectomy surgery</intervention_name>
    <description>Microincisional pars plana vitrectomy (PPV) surgery for the treatment of various vitreoretinal diseases ranging from simple to advanced cases</description>
    <arm_group_label>27-gauge pak</arm_group_label>
    <arm_group_label>23-gauge pak</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide informed consent and attend all required study visits;

          -  Requires vitrectomy in at least one eye;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Previous vitrectomy or glaucoma surgery;

          -  Planned treatment requires scleral buckling, combined procedures (eg, cataract
             surgery), silicone oil, and expansive gas other than sterile air;

          -  Treated with topical IOP lowering medication(s) at any time from baseline assessment
             to time of surgery;

          -  Pregnant or planning to become pregnant during the course of the trial;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Manager, Surgical, GCRA</last_name>
    <role>Study Director</role>
    <affiliation>Alcon, A Novartis Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2015</study_first_submitted>
  <study_first_submitted_qc>June 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2015</study_first_posted>
  <results_first_submitted>May 30, 2017</results_first_submitted>
  <results_first_submitted_qc>June 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 27, 2017</results_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 6 study centers located in the US.</recruitment_details>
      <pre_assignment_details>Of the 137 enrolled, 1 subject was exited as a screen failure prior to randomization. This reporting group includes all randomized subjects (136).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>27-Gauge</title>
          <description>CONSTELLATION® 27-gauge combined surgical pak used during vitrectomy surgery</description>
        </group>
        <group group_id="P2">
          <title>23-Gauge</title>
          <description>CONSTELLATION® 23-gauge combined surgical pak used during vitrectomy surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized and Treated</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinued prior to treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administered gas during surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all randomized subjects (Intent-to-Treat Analysis Set).</population>
      <group_list>
        <group group_id="B1">
          <title>27-Gauge</title>
          <description>CONSTELLATION® 27-gauge combined surgical pak used during vitrectomy surgery</description>
        </group>
        <group group_id="B2">
          <title>23-Gauge</title>
          <description>CONSTELLATION® 23-gauge combined surgical pak used during vitrectomy surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="136"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.8" spread="11.55"/>
                    <measurement group_id="B2" value="67.0" spread="11.65"/>
                    <measurement group_id="B3" value="66.4" spread="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Intraocular Pressure (IOP) on Operative Day</title>
        <description>IOP (fluid pressure inside the eye) was assessed using the study specified tono-pen and measured in millimeters of mercury (mmHg). Change was defined as the difference between immediate postoperative IOP and immediate preoperative IOP. A greater change in IOP may indicate a less stable posterior chamber and/or a more invasive surgery.</description>
        <time_frame>Day 0 preoperative, Day 0 postoperative</time_frame>
        <population>Intent-to-Treat Analysis Set. Number Analyzed is the number of subjects with data.</population>
        <group_list>
          <group group_id="O1">
            <title>27-Gauge</title>
            <description>CONSTELLATION® 27-gauge combined surgical pak used during vitrectomy surgery</description>
          </group>
          <group group_id="O2">
            <title>23-Gauge</title>
            <description>CONSTELLATION® 23-gauge combined surgical pak used during vitrectomy surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Intraocular Pressure (IOP) on Operative Day</title>
          <description>IOP (fluid pressure inside the eye) was assessed using the study specified tono-pen and measured in millimeters of mercury (mmHg). Change was defined as the difference between immediate postoperative IOP and immediate preoperative IOP. A greater change in IOP may indicate a less stable posterior chamber and/or a more invasive surgery.</description>
          <population>Intent-to-Treat Analysis Set. Number Analyzed is the number of subjects with data.</population>
          <units>mmHG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="6.603"/>
                    <measurement group_id="O2" value="-3.05" spread="7.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Conjunctival Edema Score at Week 1</title>
        <description>Conjunctival edema (swelling) was assessed during examination by the investigator and graded on a scale of 0-3, where 0=Absent and 3=Severe. Each sclerotomy wound was graded as infusion, vitrectomy probe, and illuminator and the average of the three was the overall Conjunctival Edema Score at the visit. Only one eye (study eye) contributed to the analysis.</description>
        <time_frame>Week 1 post operative</time_frame>
        <population>Intent-to-Treat Set. Number Analyzed is the number of subjects with data.</population>
        <group_list>
          <group group_id="O1">
            <title>27-Gauge</title>
            <description>CONSTELLATION® 27-gauge combined surgical pak used during vitrectomy surgery</description>
          </group>
          <group group_id="O2">
            <title>23-Gauge</title>
            <description>CONSTELLATION® 23-gauge combined surgical pak used during vitrectomy surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Conjunctival Edema Score at Week 1</title>
          <description>Conjunctival edema (swelling) was assessed during examination by the investigator and graded on a scale of 0-3, where 0=Absent and 3=Severe. Each sclerotomy wound was graded as infusion, vitrectomy probe, and illuminator and the average of the three was the overall Conjunctival Edema Score at the visit. Only one eye (study eye) contributed to the analysis.</description>
          <population>Intent-to-Treat Set. Number Analyzed is the number of subjects with data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.124"/>
                    <measurement group_id="O2" value="0.10" spread="0.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Post-operative Pain Rating at Day 1</title>
        <description>The subject was asked to rate post-operative pain in the study eye using a score of 0-10, where 0=no pain and 10=the worst pain imaginable.</description>
        <time_frame>Day 1 post operative</time_frame>
        <population>Intent-to-Treat Analysis Set. Number Analyzed is the number of subjects with data.</population>
        <group_list>
          <group group_id="O1">
            <title>27-Gauge</title>
            <description>CONSTELLATION® 27-gauge combined surgical pak used during vitrectomy surgery</description>
          </group>
          <group group_id="O2">
            <title>23-Gauge</title>
            <description>CONSTELLATION® 23-gauge combined surgical pak used during vitrectomy surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Post-operative Pain Rating at Day 1</title>
          <description>The subject was asked to rate post-operative pain in the study eye using a score of 0-10, where 0=no pain and 10=the worst pain imaginable.</description>
          <population>Intent-to-Treat Analysis Set. Number Analyzed is the number of subjects with data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.75"/>
                    <measurement group_id="O2" value="0.6" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected from time of consent for the duration of a subject’s participation in the study (up to 4 months).</time_frame>
      <desc>An AE was defined as any untoward medical occurrence in a subject administered a clinical trial treatment (ie, implant with an investigational device) regardless of whether the event has a causal relationship with the treatment. AEs were obtained through solicited and spontaneous comments from subjects and observations by the Investigator. Safety analysis set included all subjects/eyes exposed to the investigational device. One subject randomized to 27-gauge was treated with 23-gauge instead.</desc>
      <group_list>
        <group group_id="E1">
          <title>27-Gauge Treated Eye</title>
          <description>Ocular events, treated (study) eye</description>
        </group>
        <group group_id="E2">
          <title>27-Gauge Fellow Eye</title>
          <description>Ocular events, untreated (fellow) eye</description>
        </group>
        <group group_id="E3">
          <title>27-Gauge Systemic</title>
          <description>Non-ocular adverse events</description>
        </group>
        <group group_id="E4">
          <title>23-Gauge Treated Eye</title>
          <description>Ocular events, treated (study) eye</description>
        </group>
        <group group_id="E5">
          <title>23-Gauge Fellow Eye</title>
          <description>Ocular events, untreated (fellow) eye</description>
        </group>
        <group group_id="E6">
          <title>23-Gauge Systemic</title>
          <description>Non-ocular adverse events</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hypotony of eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Retinopathy proliferative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Craniotomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Eye laser surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Eye operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Retinal laser coagulation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Retinal operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Vitrectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Conjunctival oedema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brand Lead, Global Medical Affairs</name_or_title>
      <organization>Alcon, A Novartis Division</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

